Keunchil Park

Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Keunchil Park is a faculty member at the University of Texas MD Anderson Cancer Center, USA. His research primarily focuses on immunotherapy, specifically for advanced-stage cancers such as non-small cell lung cancer, and the genomic landscape of lung cancer in East Asia. He has contributed to numerous recent publications addressing innovative treatments and management strategies in oncology.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Alexander Drilon

Thomas Jefferson University Hospital

UNITED STATES

View details

Jonathan W. Goldman

Associate Professor

UCLA

UNITED STATES

View details

Min-Sang LEE

Soonchunhyang University Hospital Bucheon

SOUTH KOREA

View details

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES

View details

Melvin Chua

Associate Professor

Duke-NUS Medical School

SINGAPORE

View details

Chee Khoon Lee

University of Sydney

AUSTRALIA

View details

Edward B. Garon

University of California

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Keunchil Park

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

ASCO's Leadership Development Program: Focusing on the Next Generation of Leaders in Asia Pacific

Clinicopathologic and Molecular Subtyping of EGFR Mutation—Response

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

Collaborators (8)

Jianjun Zhang

Alexander Drilon

Jonathan W. Goldman

Min-Sang LEE

Catherine Shu

Melvin Chua

Chee Khoon Lee

Edward B. Garon

Make your next move.